High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors

Ilona Hapkova, Josef Skarda, Caroline Rouleau, An Thys, Cécile Notarnicola,
Maria Janikova, Florence Bernex, Miroslav Rypka, Jean-Marie Vanderwinden,
Sandrine Faure, et al.

► To cite this version:

Ilona Hapkova, Josef Skarda, Caroline Rouleau, An Thys, Cécile Notarnicola, et al.. High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors. *Experimental and Molecular Pathology*, 2013, 10.1016/j.yexmp.2012.12.004 . hal-02543718

HAL Id: hal-02543718

<https://hal.umontpellier.fr/hal-02543718>

Submitted on 15 Apr 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors

Ilona Hapkova ^{a,b}, Josef Skarda ^c, Caroline Rouleau ^{a,d}, An Thys ^e, Cécile Notarnicola ^a, Maria Janikova ^c, Florence Bernex ^a, Miroslav Rypka ^b, Jean-Marie Vanderwinden ^e, Sandrine Faure ^a, Jaroslav Vesely ^b, Pascal de Santa Barbara ^{a,*}

^a INSERM U1046, Université Montpellier 1, Université Montpellier 2, Montpellier, France

^b Department of Pathophysiology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

^c Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic

^d CHU Montpellier, Service d'Anatomie Pathologique, Montpellier, France

^e Laboratory of Neurophysiology, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium

ARTICLE INFO

Keywords:

Gastrointestinal stromal tumors (GIST)
RNA-binding protein
RBPMS2
KIT
Smooth muscle cells
Interstitial cell of Cajal

ABSTRACT

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract and are often associated with *KIT* or *PDGFRA* gene mutations. GIST cells might arise from the interstitial cells of Cajal (ICCs) or from a mesenchymal precursor that is common to ICCs and smooth muscle cells (SMCs). Here, we analyzed the mRNA and protein expression of RNA-Binding Protein with Multiple Splicing-2 (RBPMS2), an early marker of gastrointestinal SMC precursors, in human GISTs ($n=23$) by in situ hybridization, quantitative RT-PCR analysis and immunohistochemistry. The mean *RBPMS2* mRNA level in GISTs was 42-fold higher than in control gastrointestinal samples ($p<0.001$). *RBPMS2* expression was not correlated with *KIT* and *PDGFRA* expression levels, but was higher in GISTs harboring *KIT* mutations than in tumors with wild type *KIT* and *PDGFRA* or in GISTs with *PDGFRA* mutations that were characterized by the lowest *RBPMS2* levels. Moreover, *RBPMS2* levels were 64-fold higher in GIST samples with high risk of aggressive behavior than in adult control gastrointestinal samples and 6.2-fold higher in high risk than in low risk GIST specimens. *RBPMS2* protein level was high in 87% of the studied GISTs independently of their histological classification. Finally, by inhibiting the *KIT* signaling pathway in GIST882 cells, we show that *RBPMS2* expression is independent of *KIT* activation. In conclusion, *RBPMS2* is up-regulated in GISTs compared to normal adult gastrointestinal tissues, indicating that *RBPMS2* might represent a new diagnostic marker for GISTs and a potential target for cancer therapy.

Introduction

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract (Corless et al., 2011) and are highly resistant to conventional chemotherapy and radiotherapy. These tumors are characterized by the presence of activating mutations in *KIT* (75–80% frequency) or *Platelet-Derived Growth Factor Receptor Alpha* (*PDGFRA*) (5–10% of tumors), two genes encoding receptors for growth factors that are normally activated only in specific situations (Hirota et al., 1998). Imatinib mesylate, a small-molecular tyrosine kinase inhibitor that targets phosphorylation/activation of *KIT* and *PDGFRA* and also constitutively activated *KIT* and *PDGFRA* proteins, has proven efficient in GIST treatment (Joensuu et al., 2001; Tuveson et

al., 2001); however, resistance to such therapy is increasing. Therefore, the development of new-targeted therapies is strongly encouraged (Renouf et al., 2009).

It is now largely documented that post-regulatory RNA events play crucial roles in modulating differentiation and remodeling of smooth muscle tissues (Notarnicola et al., 2012; Xin et al., 2009). RNA-protein complexes control multiple steps of this process, including mRNA cellular localization, splicing, translational regulation and degradation (St Johnston, 2005). For instance, the expression of an alternative splicing isoform of the natural killer (NK) cell receptor NKp30 correlates with the prognosis of GISTs, independently from the *KIT* mutations (Delahaye et al., 2011).

Moreover, RNA-binding proteins (RBPs), which play important roles in regulating RNA metabolism, may also be deregulated in diseases, particularly in cancers during the initiation and progression phases (van Kouwenhove et al., 2011). The RNA Recognition Motif (RRM) proteins form a large RBP family which includes also RNA-Binding Protein for Multiple Splicing-2 (RBPMS2), an early marker

* Corresponding author at: INSERM U1046, 371 Avenue Doyen Giraud, 34295 Montpellier, France. Fax: +33 467 415 231.

E-mail address: Pascal.de-Santa-Barbara@inserm.fr (P. de Santa Barbara).

Table 1

Primers used for quantitative RT-PCR amplification of selected human genes.

Target transcript	Forward primer (5'-3')	Reverse primer (5'-3')	Amplicon size (bp)
<i>KIT</i>	CCT TTG CTG ATT GGT TTC G	AGG AAG TTG TGT TGG GTC TA	162
<i>TMEM16A</i>	GCT TCC GCA GGG AGG AGT A	TCG TCG GCA TCT TCA GT	162
<i>RBPM2</i>	CTC CCA TGC TGC GTT CA	GGG TGG TGT CAG AGG AAG	92
<i>PDGFRA</i>	ATG TGC CAG ACC CAG AT	CCC TCA CTG TTG TGT AAG GTT	139
<i>HPRT</i>	TGT AAT GAC CAG TCA ACA GGG	TGA CCA AGG AAA GCA AAG TCT G	136
<i>Calponin</i>	AGA AGT ATG ACC ACC AGC	CAG CCC AAT GAT GTT CCG	406
α SMA	TTC AAT GTC CCA GCC ATG TA	GAA GGA ATA GCC ACG CTC AG	222
<i>Desmin</i>	AGG AGA TGA TGG AAT ACC GAC	TTT GCT CAG GGC TGG TTT	351
<i>SM22</i>	GCA GTC CAA AAT CGA GAA GA	CTG TTG CTC CCC ATC TGA AG	503
<i>PCNA</i>	CTC CAT CCT CAA GAA GGT GTT	GGT GTC GAA GCC CTC AG	151

of gastrointestinal smooth muscle precursor cells that we identified recently (Notarnicola et al., 2012). We showed that ectopic expression of *RBPM2* in differentiated SMCs hinders their ability to contract, favors their proliferation and leads to their dedifferentiation, demonstrating that *RBPM2* expression must be tightly regulated to avoid SMC dedifferentiation (Notarnicola et al., 2012).

These results and the fact that GISTs are thought to arise from Interstitial Cells of Cajal (ICCs) or from a mesenchymal precursor that is common to ICCs and smooth muscle cells (SMCs) (Faure and de Santa Barbara, 2011; Le Guen et al., 2009; Sanders et al., 2006) prompted us to examine the mRNA and protein expression of *RBPM2* in different categories of human adult GISTs and in the GIST882 cell line. We found that *RBPM2* is up-regulated in GISTs compared to normal adult gastrointestinal tissues.

Materials and methods

Tumor samples and *KIT* and *PDGFRA* mutational analysis

Paraffin-embedded tumor samples from primary GISTs of 23 adult patients before Imatinib treatment were collected in the Department of Clinical and Molecular Pathology of the Olomouc University Hospital (Olomouc, Czech Republic). The risk of clinically aggressive behavior was evaluated according to the consensus approach published by Fletcher and coworkers (Fletcher et al., 2002). Control samples were normal gastrointestinal tissue specimens isolated from adult epithelial-derived tumors. For *KIT* and *PDGFRA* mutational analysis, genomic DNA was extracted from the paraffin-embedded GIST samples using the QIAamp DNA FFPE Tissue Kit (Qiagen). Specific PCR primers were used

Fig. 1. Expression of *RBPM2* transcripts in adult normal rectum and GIST samples. Hematoxylin–eosin (H&E) staining (upper panels) and *in situ* hybridization of smooth muscle layers sections from normal rectum and GIST samples (middle and lower panels show different magnifications of the same sections) with an anti-human *RBPM2* riboprobe. *RBPM2* transcripts are not detected in adult normal rectal musculature (arrows), whereas they are strongly expressed in tumor cells (red arrows). Bars, 50 µm (upper panels), 500 µm (middle panels) and 200 µm (lower panels).

Table 2Summary of the clinical and morphological features, risk assessment, *KIT* and *PDGFRA* mutational status as well as *KIT* and *RBPMS2* expressions in the GIST cohort.

Patient	Sex	Age (years)	Site	Morphology	Size (mm)	Risk	<i>KIT</i> or <i>PDGFRA</i> mutations	<i>KIT</i> RT-PCR	<i>RBPMS2</i> RT-PCR	<i>RBPMS2</i> IHC
1	M	73	Small intestine	Spindle	90×100×110	High Risk	Exon 9 ins AY502-503 <i>KIT</i>	+++	+++	++
2	M	73	Soft tissue	Epithelioid	12×5×12	High Risk	Exon 9 ins AY502-503 <i>KIT</i>	+++	+++	+++
3	M	74	Duodenum	Spindle	70×75×85	High Risk	Exon 9 ins AY502-503 <i>KIT</i>	++	++	+++
4	M	71	Small intestine	Spindle	14×5×14	Low Risk	Exon 11 V559D <i>KIT</i>	++	+++	+++
5	M	60	Rectum	Spindle	35×20×15	Low Risk	Exon 11 V559D <i>KIT</i>	-	++	++
6	M	71	Stomach	Mixed	15×12×10	High Risk	Exon 11 del/ins <i>KIT</i>	+++	+++	+
7	M	77	Esophagus	Spindle	22×18×40	High Risk	Exon 11 del/ins <i>KIT</i>	+++	+++	++
8	M	74	Rectum	Spindle	80×75×60	Low Risk	Exon 11 del/ins <i>KIT</i>	+	+++	++
9	M	66	Stomach	Spindle	9×5×5	Low Risk	Exon 13 K642E <i>KIT</i>	++	+++	NA
10	F	67	Stomach	Epithelioid	43×47×35	High Risk	E12 V561D <i>PDGFRA</i>	+	++	++
11	F	62	Stomach	Mixed	NA	Low Risk	Exon 18 D842Y <i>PDGFRA</i>	++	+++	NA
12	F	58	Colon	Mixed	10×10×10	Low Risk	Exon 18 silent mutation V824V <i>PDGFRA</i>	++	++	++
13	M	36	Recto-peritoneum	Mixed	65×45×42	Low Risk	Exon 18 silent mutation V824V <i>PDGFRA</i>	+	++	+
14	F	70	Esophagus	Mixed	50×30×30	Low Risk	WT	+++	+++	++
15	M	48	Esophagus	Spindle	35×25×20	High Risk	WT	+	+	++
16	M	61	Stomach	Spindle	45×25×10	Low Risk	WT	++	+++	NA
17	M	42	Small intestine	Mixed	40×30×20	High Risk	WT	+++	+++	+
18	M	60	Duodenum	Mixed	40×32×22	Low Risk	WT	++	+++	+
19	M	81	Rectum	Mixed	1×3×15	High Risk	WT	+	++	++
20	F	55	Recto-peritoneum	Epithelioid	90×70×50	High Risk	WT	+++	+++	++
21	M	65	Small intestine	Epithelioid	12×8×8	High Risk	NA	NA	NA	++
22	F	55	Small intestine	Spindle	150×13×110	High Risk	NA	NA	NA	+
23	F	60	Stomach	Spindle	50×40×50	High Risk	Exon 11 del/ins <i>KIT</i>	NA	NA	+

to analyze *KIT* exons 9, 11, 13 and 17 and *PDGFRA* exons 12, 13, 17 and 18 as previously described (Willmore-Payne et al., 2005). The GIST tissue microarray (DAA1, SuperBioChips Laboratories) contained 48 GIST and 9 normal adult gastrointestinal tissue samples. The microarray GIST samples were *KIT*-positive by immunodetection, but their *KIT* mutation status was unknown.

RNA isolation and quantitative RT-PCR

Total RNA was extracted from paraffin-embedded GIST samples using the High Pure RNA Paraffin kit (Roche Diagnostic). For quantitative RT-PCR analysis, gene expression levels were measured using the LightCycler technology (Roche Diagnostics). PCR primers (Table 1) were designed using the LightCycler Probe Design software 2.0. Each sample was assayed in three independent experiments in triplicate. Expression levels were determined with the LightCycler analysis software (version 3.5) relative to standard curves. Data were represented as the mean level of gene expression relative to the expression of the reference gene *HPRT* (Roche Diagnostic). For cell culture experiments, RNA isolation was done with the RNeasy Mini kit (Qiagen) and quantitative RT-PCR was performed using Power Sybergreen (Applied biosystems). Data were represented as the mean level of gene expression relative to the expression of the reference genes *ABL*, *TTC1* and *UBC* for the comparison of *RBPMS2* expression between different cell lines and *GAPDH* and *ACTIN* for GIST882 cells, which were treated with either Imatinib or U0126.

Production of anti-RBPMS2 antibodies and cell culture

The anti-human *RBPMS2* rabbit polyclonal antibody was raised using a synthetic peptide corresponding to the C-terminus of human *RBPMS2* (SSDTTQQGWKYRQ) (Fig. 3A). Anti-RBPMS2 antibodies were purified using protein A-sepharose and were tested by ELISA (Biotem, France).

The human GIST cell line GIST882 was maintained in DMEM (GIBCO) supplemented with 10% Fetal Bovine Serum (FBS), 2% Penicilline-Streptomycin (Lonza) and incubated with 1 μ M of Imatinib (inhibitor of *KIT* activity) (LC Laboratory) or 5 μ M of U0126 (MEK inhibitor) (Sigma-Aldrich), as previously described (Gromova et al., 2011). The human Embryonic Kidney 293 (HEK293) cell line was grown in DMEM supplemented with 10% FBS and transfected, using JetPEITM (Polyplus, France), with 5 μ g of a construct in which the full length human *RBPMS2* cDNA was subcloned in the pCS2 vector with an in frame N-terminal HA tag and the CMV promoter. Cells were analyzed after 24 h. For western blot analyses, cells were lysed and protein extracts (20 μ g) were separated on 10% polyacrylamide gels (Bio-Rad Laboratories), transferred onto nitrocellulose membranes (Amersham Hybond-ECL) and incubated with anti-RBPMS2 (home-made), anti-Tubulin (Abcam) and anti-HA (Santa Cruz Biotechnologies) primary antibodies overnight. After several washes, membranes were incubated with the relevant horseradish peroxidase-conjugated secondary antibodies (Perkin Elmer). Detection was performed by chemiluminescence (Santa Cruz Biotechnologies) on Kodak films. Tubulin expression served as a loading control.

Immunohistochemistry and in situ hybridization

Immunofluorescence and immunohistochemistry analysis of paraffin-embedded GIST sections were performed as described (Rouleau et al., 2009; Rouleau et al., 2012). Briefly, sections were deparaffinized with Histoclear (VWR, France) and rehydrated through a series of graded alcohols to PBS. For immunodetection, heat-induced antigen retrieval was carried out in 10 mM sodium citrate solution (pH 9.0). Endogenous peroxidases were inactivated by incubation in 3% H₂O₂ (Sigma-Aldrich) for 30 minutes. Anti-RBPMS2 (home-made), -Ki67 (NeoMarker), - α SMA (Sigma-Aldrich), -CD34 (Clinisciences), -S100 (Clinisciences), -KIT (Zymed), -Desmin (Euromedex) and

Fig. 2. Clinicopathological features and *RBPMS2* mRNA expression in the adult GIST cohort. (A) Results of immunohistochemical staining for *KIT* (CD117), TMEM16A, CD34, α SMA (smooth muscle actin), DESMIN and S100 ($n = 23$ GIST samples). (B and C) *KIT* (B) and *PDGFRA* (C) expression level by quantitative RT-PCR in GIST samples ($n = 20$) and in normal samples from different regions of the gastrointestinal tract as controls ($n = 5$). *KIT* and *PDGFRA* mut., GIST samples with a mutation in *KIT* or *PDGFRA*; GIST WT, GIST samples with wild type *KIT* or *PDGFRA*; NA, not available. (D) *RBPMS2* transcript level was determined by quantitative RT-PCR in GIST ($n = 20$) and in non-tumor samples from different regions of the gastrointestinal tract ($n = 5$, control). GIST WT, GIST samples with wild type *KIT* or *PDGFRA*; *KIT* and *PDGFRA* mut., GIST samples with a mutation in *KIT* or *PDGFRA*. (E) Comparison of the *RBPMS2* transcript levels in the GIST and non-tumoral samples described in A with the Mann-Whitney test ($p < 0.001$). (F) Mean expression level of *RBPMS2*, *KIT* and *PDGFRA* in GISTs that were classified based on their *KIT* and *PDGFRA* mutational status. (G) Mean expression level of *RBPMS2*, *KIT* and *PDGFRA* in GISTs that were classified according to the risk of aggressive behavior.

A

Immunohistochemistry	Positive, n (%)	Negative, n (%)	NA, n (%)	Total, n
KIT (CD117)	22 (96)	1 (4)	0 (0)	23
TMEM16A	16 (69.5)	4 (17.5)	3 (13)	23
CD34	15 (65)	4 (17.5)	4 (17.5)	23
SMOOTH MUSCLE ACTIN	9 (39)	8 (35)	6 (26)	23
DESMIN	2 (9)	12 (52)	9 (39)	23
S100	7 (30)	10 (44)	6 (26)	23

B

C

D

E

F

G

-TMEM16A (also called DOG1) (Abcam) primary antibodies were used. Specific mouse or rabbit anti-IgG biotinylated secondary antibodies were used with the avidin-peroxidase reagent (Vector) and

antibody reactions were detected with 3,3'-Diaminobenzidine (Sigma-Aldrich). As control, each GIST sections were tested without primary antibodies. Hematoxylin and Eosin (H&E) staining was performed

A

human RBPMS2 protein

MSNLKPDGEHGGSTGTGSGAGSGGALEEEVRTLFSGLPVDIKPRELYLLFRPF
KGYEGSLIKLTARQPVGFVIPDSRAGAEAAKNALNGIRFDPENPQTLRLEFAKA
NTKMAKSKLMATPNPSNVHPALGAHFIARDPYDLMGAAALIPASPEAWAPYPLY
TTELTPAISHAAFTYPTATAAAAALHAQVRWYPSSDTTQQGWKYRQFC

B

C

D

E

Immunohistochemistry	Positive, n (%)	Negative, n (%)	NA, n (%)	Total, n
KIT (CD117)	22 (96)	1 (4)	0 (0)	23
RBPMS2	20 (87)	0 (0)	3 (13)	23

F

according to standard procedures. *In situ* hybridization experiments using paraffin sections were carried out as described (Come et al., 2006; Notarnicola et al., 2012). Anti-sense riboprobes were generated by PCR amplification of human *RBPM2* cDNA using specific primer sets and subcloned in pGEM T Easy Vector (Promega, France) as previously published (Notarnicola et al., 2012). Images were acquired using a Nikon-AZ100 stereomicroscope and a Carl-Zeiss AxioImager microscope.

Statistical analysis

Statistical analysis was carried out using the Mann-Whitney test as previously described (Notarnicola et al., 2012).

Results

RBPM2 transcripts are detected in adult GISTs

To determine whether the RNA-binding protein *RBPM2* was expressed in GISTs, we first analyzed by *in situ* hybridization a commercial tissue microarray that included 48 *KIT*-positive GISTs (from low to high risk) and 9 normal adult gastrointestinal tissues (Fig. 1). The level of *RBPM2* transcripts was very low in smooth muscles of normal adult gastrointestinal tissues (black arrows, Fig. 1). Conversely, *RBPM2* was strongly expressed in 36 of the 48 GIST samples (75%), independently of their localization and the risk of aggressive behavior (red arrows, Fig. 1).

Clinicopathological features of the GIST cohort

Due to the limited clinical data and the absence of information on the *KIT* and *PDGFRA* mutational status for the GISTs included in the microarray and in order to better characterize *RBPM2* expression in GISTs, we analyzed GIST samples from a cohort of patients from Olomouc University Hospital. The group included 16 males and 7 females (male/female ratio: 1.44) with a mean age of 63.4 years (range: 36 to 81 years) who had exclusively primary GISTs located in the esophagus ($n = 4$), stomach ($n = 5$), small intestine ($n = 8$), rectum ($n = 3$), abdomen ($n = 2$) and soft tissues ($n = 1$) (Table 2). All GISTs included in this study were characterized by using classical histopathological and immunohistochemical approaches with anti-*KIT*, -*SMA*, -*CD34*, -*Desmin*, -*S100* and -*TMEM16A* (*DOG-1*) antibodies (Fig. 2A; and data not shown). GISTs were divided in spindle ($n = 11$), epithelioid ($n = 4$) and mixed cell (epithelioid and spindle) ($n = 8$) tumors based on the cell morphology (Table 2). Mitotic cells were detected with the anti-Ki67 antibody (summary in Fig. 2A) and tumors were classified as low risk ($n = 10$) or high risk ($n = 13$) as previously described (Miettinen and Lasota, 2006). *KIT* and *PDGFRA* mutational analysis was available for 21 GISTs and showed that 10 tumors (47.6%) had *KIT* mutations (three GISTs with *KIT* mutations in exon 9, six tumors with mutations in exon 11 and one tumor with a mutation in exon 13), four (19%) had a *PDGFRA* mutation (one missense and two silent mutations in exon 18 and one missense mutation in exon 12) and seven (33.4%) had wild type (WT) *KIT* and *PDGFRA* (Table 2). Quantitative RT-PCR analysis of *KIT* and *PDGFRA* expression

levels indicated, as previously published, that in all the analyzed GIST samples ($n = 20$) *KIT* and *PDGFRA* were up-regulated in comparison to normal gastrointestinal samples of adult colon, stomach and small intestine (Fig. 2B and C).

RBPM2 is strongly expressed in malignant GISTs

We then analyzed the levels of *RBPM2* transcripts in this GIST cohort and in gastrointestinal control samples by quantitative RT-PCR. In most of the analyzed GIST samples (19 of 20) *RBPM2* expression level was higher than in control samples (Fig. 2D; Table 2) and the mean *RBPM2* level in GISTs was 42-fold higher than in control samples ($p < 0.001$) (Fig. 2E). The level of *KIT* and *PDGFRA* did not significantly correlated with the amount of *RBPM2* expression in the tumors (compare Fig. 2B and C and D; data not shown). Conversely, *RBPM2* expression was higher in GISTs harboring *KIT* mutations than in tumors with wild type *KIT* and with wild type *KIT* or *PDGFRA* mutations (Fig. 2F). GISTs with *PDGFRA* mutations were characterized by the lowest *RBPM2* expression levels (Fig. 2F). Finally, *RBPM2* levels were 64-fold higher in GIST samples with high risk of aggressive behavior than in adult control digestive samples (Fig. 2G) and 6.2-fold higher in high risk than in low risk GISTs (Fig. 2G).

RBPM2 protein is highly expressed in adult GISTs

In order to examine *RBPM2* protein expression, we generated antibodies directed against the C-terminus of human *RBPM2* (Fig. 3A). The efficiency and the specificity of these anti-*RBPM2* antibodies were confirmed by western blot and immunofluorescence analyses in HEK293 cells that express HA tagged *RBPM2* (Fig. 3B, and C). In western blots, the anti-*RBPM2* antibody identified a single band of 27 kDa, corresponding to the predicted size of human *RBPM2* fused to the HA tag (Fig. 3B). In addition, this band was also detected with the anti-HA antibody (Fig. 3B). Moreover, the anti-*RBPM2*- and -HA antibodies both detected an epitope localized in the cytoplasmic compartment of such cells (Fig. 3C). Finally, the *RBPM2* signal was specifically lost when the anti-*RBPM2* antibody was pre-incubated with the *RBPM2* C-terminal peptide used to produce the antibody (data not shown). We then examined the expression of *RBPM2* by immunohistochemistry in control gastrointestinal and GIST samples (Fig. 3D–F). *RBPM2* was faintly but reproductively detected in the gastrointestinal musculature with the exception of the myenteric plexus (arrow, Fig. 3D). In contrast, it was strongly detected in 87% of the analyzed GIST samples (Fig. 3D, representative GIST sample, and Fig. 3E) and its expression level was comparable in spindle, epithelioid and mixed cell tumor variants (Fig. 3F).

RBPM2 expression and regulation in GIST882 cells

To position *RBPM2* in the *KIT* signaling pathway in GISTs, we first compared *RBPM2* expression in GIST882 (a GIST cell line homozygous for the oncogenic *KIT* mutation K641E with strong *KIT* expression and high level of *KIT* activity) (Tuveson et al., 2001), HeLa and 1321N1 (human astrocytoma) cells as well as in two prostate cancer cell lines (PC3 and LNCaP). *RBPM2* mRNA level was relatively high in

Fig. 3. *RBPM2* protein expression in adult GISTs. Characterization of the anti-human *RBPM2* antibody by immunofluorescence and western blotting (A–C). (A) Sequence of the human *RBPM2* protein (amino acids 1–209). Amino acids 195–207 of the C-terminus (in red) correspond to the sequence of the synthesized peptide used for producing the anti-*RBPM2* antibody. (B) Western blot analysis of HEK293 cells following transfection of empty vector (lane 1), the HA-TC10 (lane 2) or the HA-*RBPM2* construct (lane 3). 20 µg of whole protein extracts were processed for each condition. Tubulin (50 kDa) was used as loading protein control. HA-*RBPM2* was detected as a 27 kDa band with both anti-HA and anti-*RBPM2* antibodies. In addition, lower band corresponding to a C-terminal product of degradation was observed with only anti-HA antibodies. (C) HEK293 cells were transfected with the HA-*RBPM2* construct and then processed for immunofluorescence analysis using mouse anti-HA and anti-*RBPM2* primary antibodies and anti-mouse Alexa488 and anti-rabbit Alexa555 IgG, respectively. Nuclei were stained with Hoechst. Cytoplasmic localization of the signal is observed with both antibodies. (D) Representative example of *RBPM2* protein expression in a colonic, high risk GIST sample. Histological staining (H&E) and labeling with anti-*KIT* (CD117) and anti-*RBPM2* antibodies. In normal colon (control), *RBPM2* is expressed in vessels and the enteric myenteric plexus (arrow), but not in visceral SMCs. (E) Summary of *KIT* (CD117) and *RBPM2* protein expression in the GIST cohort ($n = 23$). NA, not available. (F) Analysis of the expression of *RBPM2* in the GIST samples that were classified based on their morphological features (spindle, mixed and epithelioid cells). Arrowhead shows vessels.

Fig. 4. *RBPMS2* mRNA expression and regulation in the GIST882 cell line. (A) Analysis of *RBPMS2* expression by quantitative RT-PCR in GIST882, HeLa, LNCAp, 1321 N1 and PC3 cells. *RBPMS2* is strongly expressed in GIST882 and HeLa cells, weakly in LNCAp and PC3 prostate cancer cells and undetectable in 1321 N1 astrocytoma cells. (B) Analysis of *RBPMS2* transcript level in GIST882 cells upon incubation with 1 μ M of Imatinib (inhibitor of KIT activity) or with DMSO alone (control DMSO) for 6, 24 and 48 h. *RBPMS2* transcript level is not influenced by inhibition of KIT activity. Control, untreated cells. (C) Analysis of *RBPMS2* transcript level in GIST882 cells following incubation with 5 μ M of U0126 (inhibitor of MEK activity) or with DMSO alone (control DMSO) for 6, 24 and 48 h. *RBPMS2* transcript level is not influenced by MEK inhibition. Control, untreated cells.

GIST882 and HeLa cells in comparison to 1321N1 cells and the two prostate cancer cell lines (Fig. 4A). Then GIST882 cells were treated with 1 μ M of Imatinib (a specific inhibitor of KIT activity) (Tuveson et al., 2001) or with 5 μ M of U0126 (a selective inhibitor of MEK which is a downstream effector of the KIT signaling pathway) for 6, 24 and 48 h (Fig. 4B, and C) and *RBPMS2* expression was determined by quantitative PCR. No significant changes in *RBPMS2* mRNA levels were observed following addition of Imatinib or U0126 in the culture medium (Fig. 4B and C).

Discussion

In this study we analyzed the expression of the RNA-binding protein RBPMS2 in a cohort of GIST samples that were classified according to their *KIT*/*PDGFRA* mutational status, risk of aggressive behavior and histological pattern (spindle, epithelioid and mixed cell phenotype).

We found that RBPMS2 mRNA and protein expression was significantly higher in GIST samples than in control gastrointestinal tissues, particularly in high-risk tumors. The levels of *KIT* and *PDGFRA* did not significantly correlate with the amount of *RBPMS2* expression. However, *RBPMS2* mRNA levels were higher in GISTs harboring *KIT* mutations than in tumors with *PDGFRA* mutations or with wild type *KIT* and *PDGFRA*. This difference could be due to the different origins of *KIT* and *PDGFRA* expressing cells and would suggest that *RBPMS2* and *KIT* expression are linked. Moreover, in the GIST882 cell line that carries the *KIT* mutation K641E and shows high KIT activity, inhibition of KIT activity using Imatinib treatment did not alter the expression of *RBPMS2*. In contrast, using primary embryonic digestive smooth muscle cultures we found that RBPMS2 over-expression induces a 2-fold increase of *KIT* mRNA level (Notarnicola et al., 2012; Notarnicola and de Santa Barbara, unpublished data). All these data suggest that KIT and RBPMS2 could be expressed in the same mesenchymal cells during the early development and remodeling of mesenchymal-derived gastrointestinal cells, or that they are part of the same signaling pathway, or share a regulatory circuitry. More experiments are needed to confirm these hypotheses and to position RBPMS2 relative to the KIT signaling pathway.

Chromosomal alterations during GIST progression have been described and could be involved in GIST prognosis (Corless et al., 2011). Specifically, losses and gains on chromosome 15 between 15q22.1 and 15q25.3 have been clearly correlated with poor outcome (Ylipää et al., 2010). As the *RBPMS2* gene is localized on chromosome 15q22.31, we can hypothesize based on our results that elimination of a negative regulatory sequence necessary for correct RBPMS2 expression could alter the endogenous expression of RBPMS2, thus favoring dedifferentiation of mesenchymal cells that will give rise to GIST tumors. A thorough

characterization of the correlation between alterations of this genome region and RBPMS2 expression is now required.

In conclusion, our study shows that most of the analyzed GISTs are characterized by abnormally elevated expression of RBPMS2, suggesting that RBPMS2 could be an indicator for tumor progression and a potential target for cancer therapy in GIST.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Contribution to authorship

Immunohistochemistry and in situ hybridization were carried out by IH with the help of CR, FB and SF under the supervision of PdSB. GIST collection and analyses were carried out by JS, MJ, and IH. Quantitative PCR analysis was performed by IH with the help of CN, and MR under the supervision of PdSB and JV. GIST cell line analyses were carried out by AT under the supervision of JMV. PdSB wrote the paper.

Funding

The work was supported by ARC (Association pour la Recherche sur le Cancer), Région Languedoc-Roussillon (Chercheur d'Avenir), INCA GSO Emergence and Ligue contre le Cancer (Comité de l'Aude) to PdSB. IH was supported by a studentship of the French Ministry of Foreign Affairs and by an IGA studentship of Palacky University, Olomouc. AT is PhD student bursary on Télémie (Belgium) grant 7.4562.10. JMV is Research Director at FRS-FNRS (Belgium).

Acknowledgments

We thank members of INSERM U1046 for helpful discussions.

References

- Come, C., Magnino, F., Bibeau, F., et al., 2006. Snail and slug play distinct roles during breast carcinoma progression. *Clinical Cancer Research* 12, 5395–5402.
- Corless, C.L., Barnett, C.M., Heinrich, M.C., 2011. Gastrointestinal stromal tumours: origin and molecular oncology. *Nature Reviews. Cancer* 11, 865–878.
- Delahaye, N.F., Rusakiewicz, S., Martins, I., et al., 2011. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. *Nature Medicine* 17, 700–707.
- Faure, S., de Santa Barbara, P., 2011. Molecular embryology of the foregut. *Journal of Pediatric Gastroenterology and Nutrition* 52, S2–S3.
- Fletcher, C.D., Berman, J.J., Corless, C., et al., 2002. Diagnosis of gastrointestinal stromal tumors: a consensus approach. *Human Pathology* 33, 459–465.

- Gromova, P., Rubin, B.P., Thys, A., et al., 2011. Neurotensin receptor 1 is expressed in gastrointestinal stromal tumors but not in interstitial cells of Cajal. *PLoS One* 6, e14710.
- Hirota, S., Isozaki, K., Moriyama, Y., et al., 1998. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science* 279, 577–580.
- Joensuu, H., Roberts, P.J., Sarlomo-Rikala, M., et al., 2001. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. *The New England Journal of Medicine* 344, 1052–1056.
- Le Guen, L., Notarnicola, C., de Santa Barbara, P., 2009. Intermuscular tendons are essential for the development of vertebrate stomach. *Development* 136, 791–801.
- Miettinen, M., Lasota, J., 2006. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. *Archives of Pathology & Laboratory Medicine* 130, 1466–1478.
- Notarnicola, C., Rouleau, C., Le Guen, L., et al., 2012. The RNA binding protein RBPMS2 regulates gastrointestinal smooth muscle development. *Gastroenterology* 143, 687–697.
- Renouf, D.J., Wilson, L., Blanke, C.D., 2009. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours. *Clinical Cancer Research* 15, 3908–3911.
- Rouleau, C., Matecki, S., Kalfa, N., et al., 2009. Activation of MAP kinase (ERK1/2) in human neonatal colonic enteric nervous system. *Neurogastroenterology and Motility* 21, 207–214.
- Rouleau, C., Rico, C., Hapkova, I., et al., 2012. Immunohistochemical analysis of bone morphological protein signaling pathway in human myometrium. *Experimental and Molecular Pathology* 93, 56–60.
- Sanders, K.M., Koh, S.D., Ward, S.M., 2006. Interstitial cells of Cajal as pacemakers in the gastrointestinal tract. *Annual Review of Physiology* 68, 307–343.
- St Johnston, D., 2005. Moving messages: the intracellular localization of mRNAs. *Nature Reviews Molecular Cell Biology* 6, 363–375.
- Tuveson, D.A., Willis, N.A., Jacks, T., et al., 2001. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. *Oncogene* 20, 5054–5058.
- van Kouwenhove, M., Kedde, M., Agami, R., 2011. MicroRNA regulation by RNA-binding proteins and its implications for cancer. *Nature Reviews. Cancer* 11, 644–656.
- Willmore-Payne, C., Layfield, L.J., Holden, J.A., 2005. C-KIT mutation analysis for diagnostic of gastrointestinal stromal tumors in fine needle aspiration specimens. *Cancer* 105, 165–170.
- Xin, M., Small, E.M., Sutherland, L.B., et al., 2009. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. *Genes & Development* 23, 2166–2178.
- Ylipää, A., Hunt, K.K., Yang, J., et al., 2010. Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. *Cancer* 117, 380–389.